A universal vaccine to protect against malaria using T cells
A universal malaria T cell vaccine based on HLA-E presentation
This study is exploring a new way to create a malaria vaccine that helps your immune system target and destroy malaria-infected cells, aiming to find a solution that works well for everyone, no matter which strain of malaria they might encounter.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11141880 on NIH RePORTER |
What this research studies
This research investigates a new approach to developing a malaria vaccine that utilizes CD8+ T cells to target and eliminate malaria-infected cells. The team aims to identify specific antigens presented by infected cells that can be targeted by these T cells, focusing on a unique molecule called MHC-E that is less variable among individuals. By using a viral vector to stimulate the immune response, the researchers hope to create a vaccine that can provide broad protection against different strains of malaria. This innovative strategy could lead to a more effective and universal malaria vaccine.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of malaria infection, particularly those living in endemic regions.
Not a fit: Patients who are not at risk of malaria or those who have already been vaccinated against malaria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective malaria vaccine that protects individuals from severe malaria infections.
How similar studies have performed: Other research has shown promise in using T cell-based vaccines for infectious diseases, but this specific approach targeting MHC-E is relatively novel.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Wilder, Brandon Keith — Oregon Health & Science University
- Study coordinator: Wilder, Brandon Keith
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.